Trastuzumab plus paclitaxel in HER-2 positive metastatic breast cancer: A single institutional experience

被引：0
|
作者：
Capobianco, A. M. L. [1 ]
Di Leo, P. [1 ]
Bochicchio, A. M. [1 ]
Coccaro, M. [1 ]
Romano, G. [1 ]
Tartarone, A. [1 ]
Ardito, R. [1 ]
Musto, C. [1 ]
Barone, M. [1 ]
Guarigli, R. [1 ]
Di Renzo, N. [1 ]
机构：
[1] Reg Hosp, Ctr Riferimento Oncol Basilicata, Div Hematol Oncol, Rionero In Vulture, Italy
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：141 / 142
页数：2
相关论文
共 50 条
  • [31] Phase II neoadjuvant trial of Interferon-gamma plus weekly paclitaxel, trastuzumab and pertuzumab in patients with HER-2 positive breast cancer
    Han, Hyo S.
    Costa, Ricardo
    Armaghani, Avan
    Soyano, Aixa
    Loftus, Loretta
    Soliman, Hatem
    Fridley, Brooke
    Whiting, Junmin
    Cerezo, Aiana
    Rosa, Marilin
    Extermann, Martine
    Khong, Hung
    Czerniecki, Brian
    CANCER RESEARCH, 2022, 82 (04)
  • [32] Trastuzumab emtansine in HER2-positive metastatic breast cancer
    Montemurro, Filippo
    LANCET ONCOLOGY, 2017, 18 (06): : 696 - 697
  • [33] Trastuzumab Deruxtecan in HER2-positive metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (08) : 670 - 670
  • [34] Trastuzumab therapy in HER2-positive, metastatic breast cancer
    Smith, A. D.
    Guilbert, K.
    Lister, D.
    Streilein, S.
    Bourrier, V. C.
    Lozar, B.
    Navaratnam, S.
    Harding, G. A.
    Pitz, M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] HER-2-positive metastatic breast cancer: trastuzumab and beyond
    Metro, Giulio
    Mottolese, Marcella
    Fabi, Alessandra
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (15) : 2583 - 2601
  • [36] A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer
    Tolaney, S. M.
    Najita, J.
    Chen, W.
    Savoie, J.
    Fornier, M.
    Krop, I. E.
    Winer, E. P.
    Bunnell, C.
    CANCER RESEARCH, 2009, 69 (02) : 243S - 243S
  • [37] Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer
    Gennari, Alessandra
    De Tursi, Michele
    Carella, Consiglia
    Ricevuto, Enrico
    Orlandini, Cinzia
    Frassoldati, Antonio
    Conte, Pierfranco
    Bruzzi, Paolo
    Iacobelli, Stefano
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 115 (01) : 131 - 136
  • [38] Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival
    Rober, NJ
    Leyland-Jones, B
    Asmar, L
    Belt, RJ
    Ilegbodu, D
    Loesch, DM
    Raju, RN
    Cobleigh, M
    Albain, KS
    Slamom, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 20S - 20S
  • [39] Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer
    Alessandra Gennari
    Michele De Tursi
    Consiglia Carella
    Enrico Ricevuto
    Cinzia Orlandini
    Antonio Frassoldati
    Pierfranco Conte
    Paolo Bruzzi
    Stefano Iacobelli
    Breast Cancer Research and Treatment, 2009, 115 : 131 - 136
  • [40] An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
    Esteva, Francisco J.
    Franco, Sandra X.
    Hagan, Maura K.
    Brewster, Abenaa M.
    Somer, Robert A.
    Williams, Will
    Florance, Allison M.
    Turner, Simon
    Stein, Steven
    Perez, Alejandra
    ONCOLOGIST, 2013, 18 (06): : 661 - 666
12345